There are 2789 resources available
1309P - A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)
Presenter: Martin Reck
Session: ePoster Display
1310P - Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
Presenter: man Jiang
Session: ePoster Display
1379P - Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
Presenter: Daniel Catenacci
Session: ePoster Display
1315P - Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
Presenter: Sandra Llop Serna
Session: ePoster Display
1381P - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
Presenter: Markus Moehler
Session: ePoster Display
1382P - Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer
Presenter: Jeeyun Lee
Session: ePoster Display
1383P - Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer
Presenter: Yasutoshi Kuboki
Session: ePoster Display
1384P - DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Presenter: Samuel Klempner
Session: ePoster Display
1385P - Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)
Presenter: Zhao-qing Tang
Session: ePoster Display